Association of Community Cancer Centers Honors Anne Arundel Medical Center’s Geaton and JoAnn DeCesaris Cancer Institute for Its Rapid Access Chest and Lung Assessment Program
May 28, 2012, Rockville, MD – Anne Arundel Medical Center’s Geaton and JoAnn DeCesaris Cancer Institute, Annapolis, Md., has been selected to receive special recognition by the Association of Community Cancer Centers (ACCC). Anne Arundel Medical Center’s Geaton and JoAnn DeCesaris Cancer Institute will receive a 2012 ACCC Innovator Award, sponsored by GE Healthcare, which honors ACCC-member cancer programs that have exhibited forward-thinking strategic planning and developed pioneering programs and replicable models. ACCC is the leading national multidisciplinary organization that sets the standard for quality care for patients with cancer.
Anne Arundel Medical Center’s Geaton and JoAnn DeCesaris Cancer Institute will be recognized at the ACCC 29th National Oncology Conference in San Antonio, Tex., on October 3-6, 2012, and share its creative solution and outstanding program with meeting attendees.
Only eight cancer programs nationwide were selected to receive a 2012 ACCC Innovator Award. Anne Arundel Medical Center’s Geaton and JoAnn DeCesaris Cancer Institute was selected for its innovative coordinated, multidisciplinary approach for patients with abnormal chest findings, which leads to expedited referrals and better management.
Often in the community setting, patients found to have abnormal chest imaging, especially pulmonary nodules, are followed by their primary care providers who may be left to manage complex pulmonary findings on their own. In the Rapid Access Chest and Lung Assessment Program, providers in the community, as well as those within the hospital and the emergency department, can contact the program coordinator about any patient with any abnormal chest finding. A patient’s imaging is reviewed by a multidisciplinary team that includes a pulmonologist, thoracic surgeon, thoracic radiologist, and nurse navigator. The average wait from abnormal findings by imaging to evaluation is an average of one to two days. Patients and referring providers appreciate the timely feedback and expedited management.
Both ACCC and GE Healthcare will highlight this innovative program to oncology care providers as well as to the broader healthcare community across the country. The commitment to helping clinicians improve care for patients with cancer is shared by ACCC and GE. GE Healthcare’s sponsorship of the ACCC Innovator Awards will help catalyze cancer innovation in the community setting.
Since 1974, the Association of Community Cancer Centers (ACCC) has served as the leading national multidisciplinary organization that sets the standard for quality care for patients with cancer. ACCC is dedicated to promoting professional learning opportunities and to providing a forum for members to network and enhance their skills in the business, clinical and management aspects of care for the cancer community. More than 17,000 cancer care professionals from approximately 900 hospitals and more than 1,200 private practices are affiliated with ACCC. ACCC’s unique membership includes all members of the cancer care team: medical and radiation oncologists, surgeons, cancer program administrators and medical directors, pharmacists, oncology nurses, oncology social workers, and cancer program data managers. For more information, visit ACCC’s website at www.accc-cancer.org, Facebook, Twitter, and on ACCC’s blog, ACCCBuzz, at www.acccbuzz.wordpress.com.
GE Healthcare offers a wide portfolio for oncology and a strategy that combines cellular research, medical imaging, laboratory diagnostics, biopharmaceutical manufacturing technologies, and information technology. These innovative technologies help the oncology community increase their understanding of the causes and progression of cancer and can help physicians make more personalized cancer treatment and management decisions. Recently, GE launched a global healthymagination commitment to help deliver better care to 10 million patients by 2020 through $1 billion in dedicated R&D investment aimed at accelerating cancer treatment progress through innovation.